Featured
Read our handpicked blogs, curated for you.
|
CMOs do not struggle to justify campaigns; they struggle to prove Marketing ROI with hard numbers the board trusts. If…
|
Pharma marketers in India know the frustration well. Campaigns stall not because the idea is weak, but because the…
|
For Indian pharma, HCP engagement is no longer about reach; it’s about relevance and measurable impact. Boards want to…
Recent releases
|
Digital-First Doesn’t Mean Doctor-Last: Balancing Automation with Empathy
The digital-first trap: Every pharma boardroom today is chasing “digital-first.” It sounds good on slides. Automated campaigns. AI-driven targeting. CRM dashboards glowing with data. But here’s the…
|
Breaking the Disconnect Between Sales and Marketing with Smart Tech
The disconnect nobody wants to admit: Walk into any pharma company and ask sales what they think of marketing. You’ll hear: “They create campaigns we can’t use in the field.” Ask marketing what they…
|
Why Personalization in Pharma is Not Optional Anymore
Pharma has reached a turning point. Doctors don’t want generic detailers sent in bulk. Patients don’t trust one-size-fits-all education campaigns. Regulators demand accuracy, and competitors are…
|
Schedule H, MLR Reviews, and Tech: Making Compliance Invisible
Compliance is the make-or-break factor in pharma marketing; creativity means nothing if compliance collapses. Every CMO in India knows this. Schedule H drugs come with strict guidelines. UCPMP 2024…
